Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8

Stage III includes: (T4a, N1, M0); (T3, N2, M0); (T2, N3, M0); (T4b, N0, M0); (T4b, N1, M0); (T4a, N2, M0); (T3, N3, M0); (T4b, N2, M0); (T4b, N3, M0); (T4a, N3, M0). T2: Tumor invades the muscularis propria. T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). T4b: Tumor invades adjacent structures/organs. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8

biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)


Clinical Stage IIA Gastric Cancer AJCC v8

Stage IIA includes: (T1, N1, N2, or N3, M0); (T2, N1, N2, or N3, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Clinical Stage IIB Gastric Cancer AJCC v8

Stage IIB includes: (T3, N0, M0); (T4a, N0, M0). T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Recurrent Head and Neck Squamous Cell Carcinoma

The reemergence of squamous cell carcinoma in the head and neck region after a period of remission.


Locally Advanced Paraganglioma

A paraganglioma that has spread from its original site of growth to nearby tissues or lymph nodes.


Refractory Primary Amyloidosis

Primary amyloidosis that does not respond to treatment.


Recurrent Primary Amyloidosis

The reemergence of primary amyloidosis after a period of remission.


Classical Hodgkin lymphoma refractory

Classic Hodgkin lymphoma that is resistant to treatment.


Stage I Anal Cancer AJCC v8

Stage I includes: T1, N0, M0. T1: Tumor 2 cm or smaller. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage II Anal Cancer AJCC v8

Stage II includes: IIA: T2, N0, M0; IIB: T3, N0, M0. T2: Tumor larger than 2 cm but equal to or smaller than 5 cm. T3: Tumor larger than 5 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIA Anal Cancer AJCC v8

Stage IIA includes: T2, N0, M0. T2: Tumor larger than 2 cm but equal to or smaller than 5 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIB Anal Cancer AJCC v8

Stage IIB includes: T3, N0, M0. T3: Tumor larger than 5 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage III Anal Cancer AJCC v8

Stage III includes: IIIA: (T1, N1, M0); (T2, N1, M0); IIIB: (T4, N0, M0); IIIC: (T3, N1, M0); (T4, N1, M0). T1: Tumor 2 cm or smaller. T2: Tumor larger than 2 cm but equal to or smaller than 5 cm. T3: Tumor larger than 5 cm. T4: Tumor of any size invading adjacent organ(s), such as the vagina, urethra, or bladder. N0: No regional lymph node metastasis. N1: Metastasis in inguinal, mesorectal, internal iliac, or external iliac nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIA Anal Cancer AJCC v8

Stage IIIA includes: (T1, N1, M0); (T2, N1, M0). T1: Tumor 2 cm or smaller. T2: Tumor larger than 2 cm but equal to or smaller than 5 cm. N1: Metastasis in inguinal, mesorectal, internal iliac, or external iliac nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIB Anal Cancer AJCC v8

Stage IIIB includes: T4, N0, M0. T4: Tumor of any size invading adjacent organ(s), such as the vagina, urethra, or bladder. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIC Anal Cancer AJCC v8

Stage IIIC includes: (T3, N1, M0); (T4, N1, M0). T3: Tumor larger than 5 cm. T4: Tumor of any size invading adjacent organ(s), such as the vagina, urethra, or bladder. N1: Metastasis in inguinal, mesorectal, internal iliac, or external iliac nodes. M0: No distant metastasis. (AJCC 8th ed.)


PRAME Positive

biolink:PhenotypicFeature biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

An indication that PRAME expression has been detected in a sample.


Metastatic Digestive System Carcinoma

A carcinoma that arises from the gastrointestinal system and has metastasized to other anatomic sites.


Stage III Small Intestinal Adenocarcinoma AJCC v8

Stage III includes: IIIA: Any T, N1, M0; IIIB: Any T, N2, M0. N1: Metastasis in one or two regional lymph nodes. N2: Metastasis in three or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIA Small Intestinal Adenocarcinoma AJCC v8

Stage IIIA includes: Any T, N1, M0. N1: Metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIB Small Intestinal Adenocarcinoma AJCC v8

Stage IIIB includes: Any T, N2, M0. N2: Metastasis in three or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage IV Small Intestinal Adenocarcinoma AJCC v8

Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)


Stage IV Appendix Carcinoma AJCC v8

Stage IV includes: IVA: (Any T, N0, M1a); (Any T, Any N, M1b, G1); IVB: (Any T, Any N, M1b, G2, G3, or GX); IVC: (Any T, Any N, M1c, Any G). N0: No regional lymph node metastasis. M1a: Intraperitoneal acellular mucin, without identifiable tumor cells in the disseminated peritoneal mucinous deposits. M1b: Intraperitoneal metastasis only, including peritoneal mucinous deposits containing tumor cells. M1c: Metastasis to sites other than peritoneum. G1: Well differentiated. G2: Moderately differentiated. G3: Poorly differentiated. GX: Grade cannot be assessed. (AJCC 8th ed.)


Stage IVA Appendix Carcinoma AJCC v8

Stage IVA includes: (Any T, N0, M1a); (Any T, Any N, M1b, G1). N0: No regional lymph node metastasis. M1a: Intraperitoneal acellular mucin, without identifiable tumor cells in the disseminated peritoneal mucinous deposits. M1b: Intraperitoneal metastasis only, including peritoneal mucinous deposits containing tumor cells. G1: Well differentiated. (AJCC 8th ed.)


Stage IVB Appendix Carcinoma AJCC v8

Stage IVB includes: Any T, Any N, M1b, G2, G3, or GX. M1b: Intraperitoneal metastasis only, including peritoneal mucinous deposits containing tumor cells. G2: Moderately differentiated. G3: Poorly differentiated. GX: Grade cannot be assessed.  (AJCC 8th ed.)


Stage IVC Appendix Carcinoma AJCC v8

Stage IVC includes: Any T, Any N, M1c, Any G. M1c: Metastasis to sites other than peritoneum. (AJCC 8th ed.)


Refractory Neuroblastoma

A neuroblastoma that does not respond to treatment.


Refractory Lymphoma

A lymphoma that does not respond to treatment.


Recurrent Lymphoma

The reemergence of a lymphoma after a period of remission.


Refractory Histiocytic and Dendritic Cell Neoplasm

A histiocytic and dendritic cell neoplasm that does not respond to treatment.


Recurrent Histiocytic and Dendritic Cell Neoplasm

The reemergence of a histiocytic and dendritic cell neoplasm after a period of remission.


Recurrent Langerhans Cell Histiocytosis

The reemergence of Langerhans cell histiocytosis after a period of remission.


Refractory Langerhans Cell Histiocytosis

Langerhans cell histiocytosis that does not respond to treatment.


Stage 0 Colorectal Cancer AJCC v8

Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ, intramucosal carcinoma (involvement of lamina propria with no extension through muscularis mucosae). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage I Colorectal Cancer AJCC v8

Stage I includes: (T1, N0, M0); (T2, N0, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage II Colorectal Cancer AJCC v8

Stage II includes: IIA: T3, N0, M0; IIB: T4a, N0, M0; IIC: T4b, N0, M0. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIA Colorectal Cancer AJCC v8

Stage IIA includes: T3, N0, M0. T3: Tumor invades through the muscularis propria into pericolorectal tissues. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIB Colorectal Cancer AJCC v8

Stage IIB includes: T4a, N0, M0. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIC Colorectal Cancer AJCC v8

Stage IIC includes: T4b, N0, M0. T4b: Tumor directly invades or adheres to adjacent organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage III Colorectal Cancer AJCC v8

Stage III includes: IIIA: (T1-T2, N1/N1c, M0); (T1, N2a, M0); IIIB: (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0); IIIC: (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2: Four or more regional lymph nodes are positive. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIA Colorectal Cancer AJCC v8

Stage IIIA includes: (T1-T2, N1/N1c, M0); (T1, N2a, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2a: Four to six regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIB Colorectal Cancer AJCC v8

Stage IIIB includes: (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIC Colorectal Cancer AJCC v8

Stage IIIC includes: (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0). T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N2: Four or more regional lymph nodes are positive. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)


Stage IV Colorectal Cancer AJCC v8

Stage IV includes: IVA: (Any T, Any N, M1a); IVB: (Any T, Any N, M1b); IVC: (Any T, Any N, M1c). M1a: Metastasis to one site or organ without peritoneal metastasis. M1b: Metastasis to two or more sites or organs without peritoneal metastasis. M1c: Metastasis to the peritoneal surface alone or with other site or organ metastases. (AJCC 8th ed.)


Stage IVA Colorectal Cancer AJCC v8

Stage IVA includes: Any T, Any N, M1a. M1a: Metastasis to one site or organ without peritoneal metastasis. (AJCC 8th ed.)


Stage IVB Colorectal Cancer AJCC v8

Stage IVB includes: Any T, Any N, M1b. M1b: Metastasis to two or more sites or organs without peritoneal metastasis.  (AJCC 8th ed.)


Stage IVC Colorectal Cancer AJCC v8

Stage IVC includes: Any T, Any N, M1c. M1c: Metastasis to the peritoneal surface alone or with other site or organ metastases. (AJCC 8th ed.)


Refractory acute myeloid leukemia

Acute myeloid leukemia that does not respond to treatment.


BRAF V600 Wild Type

A genetic finding indicating that codon 600 of the BRAF gene encodes the wild type amino acid, valine.


Stage I Hepatocellular Carcinoma AJCC v8

Stage I includes: IA (T1a, N0, M0); IB (T1b, N0, M0). T1a: Solitary tumor equal to or less than 2 cm.  T1b: Solitary tumor larger than 2 cm without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IA Hepatocellular Carcinoma AJCC v8

Stage IA includes: T1a, N0, M0. T1a: Solitary tumor equal to or less than 2 cm.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IB Hepatocellular Carcinoma AJCC v8

Stage IB includes: T1b, N0, M0. T1b: Solitary tumor larger than 2 cm without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage II Hepatocellular Carcinoma AJCC v8

Stage II includes: T2, N0, M0. T2: Solitary tumor larger than 2 cm with vascular invasion, or multiple tumors, none larger than 5 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage III Hepatocellular Carcinoma AJCC v8

Stage III includes: IIIA: (T3, N0, M0); IIIB: (T4, N0, M0). T3: Multiple tumors, at least one of which is larger than 5 cm. T4: Single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein, or tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIA Hepatocellular Carcinoma AJCC v8

Stage IIIA includes: T3, N0, M0. T3: Multiple tumors, at least one of which is larger than 5 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIB Hepatocellular Carcinoma AJCC v8

Stage IIIB includes: T4, N0, M0. T4: Single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein, or tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IV Hepatocellular Carcinoma AJCC v8

Stage IV includes: IVA: (Any T, N1, M0); IVB: (Any T, Any N, M1). N1: Regional lymph node metastasis. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)


Stage IVA Hepatocellular Carcinoma AJCC v8

Stage IVA includes: Any T, N1, M0. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IVB Hepatocellular Carcinoma AJCC v8

Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)


Stage III Intrahepatic Bile Duct Cancer AJCC v8

Stage III includes: IIIA: (T3, N0, M0); IIIB: (T4, N0, M0); (Any T, N1, M0). T3: Tumor perforating the visceral peritoneum. T4: Tumor involving local extrahepatic structures by direct invasion. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8

Stage IIIA includes: T3, N0, M0. T3: Tumor perforating the visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8

Stage IIIB includes: (T4, N0, M0); (Any T, N1, M0). T4: Tumor involving local extrahepatic structures by direct invasion. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IV Intrahepatic Bile Duct Cancer AJCC v8

Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)


Stage I Gallbladder Cancer AJCC v8

Stage I includes: T1, N0, M0. T1: Tumor invading the lamina propria or muscular layer. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage II Gallbladder Cancer AJCC v8

Stage II includes: IIA: T2a, N0, M0; IIB: T2b, N0, M0. T2a: Tumor invading the perimuscular connective tissue on the peritoneal side, without involvement of the serosa (visceral peritoneum). T2b: Tumor invading the perimuscular connective tissue on the hepatic side, with no extension into the liver. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIA Gallbladder Cancer AJCC v8

Stage IIA includes: T2a, N0, M0. T2a: Tumor invading the perimuscular connective tissue on the peritoneal side, without involvement of the serosa (visceral peritoneum). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIB Gallbladder Cancer AJCC v8

Stage IIB includes: T2b, N0, M0. T2b: Tumor invading the perimuscular connective tissue on the hepatic side, with no extension into the liver. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage III Gallbladder Cancer AJCC v8

Stage III includes: IIIA: (T3, N0, M0); IIIB: (T1-3, N1, M0). T1: Tumor invading the lamina propria or muscular layer. T2: Tumor invading the perimuscular connective tissue on the peritoneal side, without involvement of the serosa (visceral peritoneum); or tumor invading the perimuscular connective tissue on the hepatic side, with no extension into the liver. T3: Tumor perforating the serosa (visceral peritoneum) and/or directly invading the liver and/or one other adjacent organ or structure, such as the stomach, duodenum, colon, pancreas, omentum, or extrahepatic bile ducts. N0: No regional lymph node metastasis. N1: Metastases to one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIA Gallbladder Cancer AJCC v8

Stage IIIA includes: T3, N0, M0. T3: Tumor perforating the serosa (visceral peritoneum) and/or directly invading the liver and/or one other adjacent organ or structure, such as the stomach, duodenum, colon, pancreas, omentum, or extrahepatic bile ducts. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIB Gallbladder Cancer AJCC v8

Stage IIIB includes: T1-3, N1, M0. T1: Tumor invading the lamina propria or muscular layer. T2: Tumor invading the perimuscular connective tissue on the peritoneal side, without involvement of the serosa (visceral peritoneum); or tumor invading the perimuscular connective tissue on the hepatic side, with no extension into the liver. T3: Tumor perforating the serosa (visceral peritoneum) and/or directly invading the liver and/or one other adjacent organ or structure, such as the stomach, duodenum, colon, pancreas, omentum, or extrahepatic bile ducts. N1: Metastases to one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage IV Gallbladder Cancer AJCC v8

Stage IV includes: IVA: T4, N0-1, M0; IVB: (Any T, N2, M0); (Any T, Any N, M1). T4: Tumor invading the main portal vein or hepatic artery or invading two or more extrahepatic organs or structures. N0: No regional lymph node metastasis. N1: Metastases to one to three regional lymph nodes. N2: Metastases to four or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)


Stage IVA Gallbladder Cancer AJCC v8

Stage IVA includes: T4, N0-1, M0. T4: Tumor invading the main portal vein or hepatic artery or invading two or more extrahepatic organs or structures. N0: No regional lymph node metastasis. N1: Metastases to one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage IVB Gallbladder Cancer AJCC v8

Stage IVB includes: (Any T, N2, M0); (Any T, Any N, M1). N2: Metastases to four or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)


Stage III Hilar Cholangiocarcinoma AJCC v8

Stage III includes: IIIA: (T3, N0, M0); IIIB: (T4, N0, M0); IIIC: (Any T, N1, M0). T3: Tumor invading unilateral branches of the portal vein or hepatic artery. T4: Tumor invading the main portal vein or its branches bilaterally, or the common hepatic artery; or unilateral second-order biliary radicals with contralateral portal vein or hepatic artery involvement. N0: No regional lymph node metastasis. N1: One to three positive lymph nodes typically involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage IV Hilar Cholangiocarcinoma AJCC v8

Stage IV includes: IVA: (Any T, N2, M0); IVB: (Any T, Any N, M1). N2: Four or more positive lymph nodes involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)


Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8

Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ (intraductal tumor). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage I Intrahepatic Cholangiocarcinoma AJCC v8

Stage I includes: IA (T1a, N0, M0); IB (T1b, N0, M0). T1a: Solitary tumor equal or less than 5 cm without vascular invasion.  T1b: Solitary tumor larger than 5 cm without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IB Intrahepatic Cholangiocarcinoma AJCC v8

Stage IB includes: T1b, N0, M0. T1b: Solitary tumor larger than 5 cm without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage II Intrahepatic Cholangiocarcinoma AJCC v8

Stage II includes: T2, N0, M0. T2: Solitary tumor with intrahepatic vascular invasion, or multiple tumors, with or without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage III Intrahepatic Cholangiocarcinoma AJCC v8

Stage III includes: IIIA: (T3, N0, M0); IIIB: (T4, N0, M0); (Any T, N1, M0). T3: Tumor perforating the visceral peritoneum. T4: Tumor involving local extrahepatic structures by direct invasion. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8

Stage IIIA includes: T3, N0, M0. T3: Tumor perforating the visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8

Stage IIIB includes: (T4, N0, M0); (Any T, N1, M0). T4: Tumor involving local extrahepatic structures by direct invasion. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IV Intrahepatic Cholangiocarcinoma AJCC v8

Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)


Stage III Distal Bile Duct Cancer AJCC v8

Stage III includes: IIIA: (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); IIIB: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T1: Tumor invading the bile duct wall with a depth less than 5 mm. T2: Tumor invading the bile duct wall with a depth of 5-12 mm. T3: Tumor invading the bile duct wall with a depth greater than 12 mm. T4: Tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIA Distal Bile Duct Cancer AJCC v8

Stage IIIA includes: (T1, N2, M0); (T2, N2, M0); (T3, N2, M0). T1: Tumor invading the bile duct wall with a depth less than 5 mm. T2: Tumor invading the bile duct wall with a depth of 5-12 mm. T3: Tumor invading the bile duct wall with a depth greater than 12 mm. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIB Distal Bile Duct Cancer AJCC v8

Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage IV Distal Bile Duct Cancer AJCC v8


Recurrent B Acute Lymphoblastic Leukemia, BCR-ABL1-Like

The reemergence of  B-acute lymphoblastic leukemia, BCR-ABL1-like after a period of remission.


Refractory B Acute Lymphoblastic Leukemia, BCR-ABL1-Like

B-acute lymphoblastic leukemia, BCR-ABL1-like that does not respond to treatment.


Stage III Ampulla of Vater Cancer AJCC v8

Stage III includes: IIIA: (T1a, N1, M0); (T1b, N1, M0); (T2, N1, M0); (T3a, N1, M0); (T3b, N1, M0); IIIB: (T4, Any N, M0); (Any T, N2, M0). T1a: Tumor limited to ampulla of Vater or sphincter of Oddi. T1b: Tumor invading beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa. T2: Tumor invading into the muscularis propria of the duodenum. T3a: Tumor directly invading the pancreas (up to 0.5 cm). T3b: Tumor extending more than 0.5 cm into the pancreas, or extending into peripancreatic tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery. T4: Tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery, irrespective of size. N1: Metastasis to one to three regional lymph nodes. N2: Metastasis to four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIA Ampulla of Vater Cancer AJCC v8

Stage IIIA includes: (T1a, N1, M0); (T1b, N1, M0); (T2, N1, M0); (T3a, N1, M0); (T3b, N1, M0). T1a: Tumor limited to ampulla of Vater or sphincter of Oddi. T1b: Tumor invading beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa. T2: Tumor invading into the muscularis propria of the duodenum. T3a: Tumor directly invading the pancreas (up to 0.5 cm). T3b: Tumor extending more than 0.5 cm into the pancreas, or extending into peripancreatic tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery. N1: Metastasis to one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIB Ampulla of Vater Cancer AJCC v8

Stage IIIB includes: (T4, Any N, M0); (Any T, N2, M0). T4: Tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery, irrespective of size. N2: Metastasis to four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage IV Ampulla of Vater Cancer AJCC v8


Stage 0 Pancreatic Cancer AJCC v8

Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. This includes high-grade pancreatic intraepithelial neoplasia (PanIn-3), intraductal papillary mucinous neoplasm with high-grade dysplasia, intraductal tubulopapillary neoplasm with high-grade dysplasia, and mucinous cystic neoplasm with high-grade dysplasia.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage I Pancreatic Cancer AJCC v8

Stage I includes: IA: (T1, N0, M0); IB: (T2, N0, M0). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IA Pancreatic Cancer AJCC v8

Stage IA includes: T1, N0, M0. T1: Tumor measuring 2 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IB Pancreatic Cancer AJCC v8

Stage IB includes: T2, N0, M0. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage II Pancreatic Cancer AJCC v8

Stage II includes: IIA: (T3, N0, M0); IIB: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. T3: Tumor measuring more than 4 cm in greatest dimension. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIA Pancreatic Cancer AJCC v8

Stage IIA includes: T3, N0, M0. T3: Tumor measuring more than 4 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIB Pancreatic Cancer AJCC v8

Stage IIB includes: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. T3: Tumor measuring more than 4 cm in greatest dimension. N1: Metastasis in one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage III Pancreatic Cancer AJCC v8

Stage III includes: (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. T3: Tumor measuring more than 4 cm in greatest dimension. T4: Tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery, regardless of size. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage IV Pancreatic Cancer AJCC v8

Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)


Stage I Pancreatic Neuroendocrine Tumor AJCC v8

Stage I includes: T1, N0, M0. T1: Tumor limited to the pancreas and measuring less than 2 cm. N0: No regional lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)


Stage II Pancreatic Neuroendocrine Tumor AJCC v8

Stage II includes: (T2, N0, M0); (T3, N0, M0). T2: Tumor limited to the pancreas and measuring 2-4 cm. T3: Tumor limited to the pancreas and measuring more than 4 cm; or tumor invading the duodenum or bile duct. N0: No regional lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)


Stage III Pancreatic Neuroendocrine Tumor AJCC v8

Stage III includes: (T4, N0, M0); (Any T, N1, M0). T4: Tumor invading adjacent organs (stomach, spleen, colon, adrenal gland) or the wall of large vessels (celiac axis or the superior mesenteric artery). N0: No regional lymph node involvement. N1: Regional lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)


Stage IV Pancreatic Neuroendocrine Tumor AJCC v8


MET Fusion Gene Positive

An indication that a MET fusion gene has been detected in a sample.


Stage III Thymoma AJCC v8

Stage III includes: IIIA: (T3, N0, M0); IIIB: (T4, N0, M0). T3: Tumor with direct invasion into any of the following: lung, brachiocephalic vein, superior vena cava, phrenic nerve, chest wall, or extrapericardial pulmonary artery or veins. T4: Tumor with invasion into any of the following: aorta (ascending, arch, or descending), arch vessels, intrapericardial pulmonary artery, myocardium, trachea, esophagus. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIA Thymoma AJCC v8

Stage IIIA includes: T3, N0, M0. T3: Tumor with direct invasion into any of the following: lung, brachiocephalic vein, superior vena cava, phrenic nerve, chest wall, or extrapericardial pulmonary artery or veins. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIB Thymoma AJCC v8

Stage IIIB includes: T4, N0, M0. T4: Tumor with invasion into any of the following: aorta (ascending, arch, or descending), arch vessels, intrapericardial pulmonary artery, myocardium, trachea, esophagus. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IV Thymoma AJCC v8

Stage IV includes: IVA: (Any T, N1, M0); (Any T, N0,1, M1a); IVB: (Any T, N2, M0, M1a); (Any T, Any N, M1b). N0: No regional lymph node metastasis. N1: Metastasis in anterior (perithymic) lymph nodes. N2: Metastasis in deep intrathoracic or cervical lymph nodes. M0: No distant metastasis. M1a: Separate pleural or pericardial nodule(s). M1b: Pulmonary intraparenchymal nodule or distant organ metastasis. (AJCC 8th ed.)


Stage IVA Thymoma AJCC v8

Stage IVA includes: (Any T, N1, M0); (Any T, N0,1, M1a). N0: No regional lymph node metastasis. N1: Metastasis in anterior (perithymic) lymph nodes. M0: No distant metastasis. M1a: Separate pleural or pericardial nodule(s). (AJCC 8th ed.)


Stage IVB Thymoma AJCC v8

Stage IVB includes: (Any T, N2, M0, M1a); (Any T, Any N, M1b). N2: Metastasis in deep intrathoracic or cervical lymph nodes. M0: No distant metastasis. M1a: Separate pleural or pericardial nodule(s). M1b: Pulmonary intraparenchymal nodule or distant organ metastasis. (AJCC 8th ed.)


Stage I Pleural Malignant Mesothelioma AJCC v8

Stage I includes: IA: (T1, N0, M0); IB: (T2 or T3, N0, M0). T1: Tumor limited to the ipsilateral parietal with or without involvement of visceral pleura, mediastinal pleura, and diaphragmatic pleura. T2: Tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of diaphragmatic muscle and/or extension of tumor from visceral pleura into the underlying pulmonary parenchyma. T3: Tumor is locally advanced but potentially resectable. The tumor involves all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of the endothoracic fascia, extension into the mediastinal fat, solitary, completely resectable focus of tumor extending into the soft tissues of the chest wall, and/or nontransmural involvement of the pericardium. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


Stage IB Pleural Malignant Mesothelioma AJCC v8

Stage IB includes: T2 or T3, N0, M0. T2: Tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of diaphragmatic muscle and/or extension of tumor from visceral pleura into the underlying pulmonary parenchyma. T3: Tumor is locally advanced but potentially resectable. The tumor involves all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of the endothoracic fascia, extension into the mediastinal fat, solitary, completely resectable focus of tumor extending into the soft tissues of the chest wall, and/or nontransmural involvement of the pericardium. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


Stage II Pleural Malignant Mesothelioma AJCC v8

Stage II includes: (T1, N1, M0); (T2, N1, M0). T1: Tumor limited to the ipsilateral parietal with or without involvement of visceral pleura, mediastinal pleura, and diaphragmatic pleura. T2: Tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of diaphragmatic muscle and/or extension of tumor from visceral pleura into the underlying pulmonary parenchyma. N1: Metastases in the ipsilateral bronchopulmonary, hilar, or mediastinal (including the internal mammary, peridiaphragmatic, pericardial fat pad, or intercostal) lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage III Pleural Malignant Mesothelioma AJCC v8

Stage III includes: IIIA: (T3, N1, M0); IIIB: (T1-3, N2, M0); (T4, Any N, M0). T1: Tumor limited to the ipsilateral parietal with or without involvement of visceral pleura, mediastinal pleura, and diaphragmatic pleura. T2: Tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of diaphragmatic muscle and/or extension of tumor from visceral pleura into the underlying pulmonary parenchyma. T3: Tumor is locally advanced but potentially resectable. The tumor involves all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of the endothoracic fascia, extension into the mediastinal fat, solitary, completely resectable focus of tumor extending into the soft tissues of the chest wall, and/or nontransmural involvement of the pericardium. T4: Tumor is locally advanced and technically unresectable. The tumor involves all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: diffuse extension or multifocal masses of tumor in the chest wall, with or without associated rib destruction, direct transdiaphragmatic extension of tumor to the peritoneum, direct extension of tumor to the contralateral pleura, direct extension of tumor to mediastinal organs, direct extension of tumor into the spine, and/or tumor extending through to the internal surface of the pericardium with or without a pericardial effusion; or tumor involving the myocardium. N1: Metastases in the ipsilateral bronchopulmonary, hilar, or mediastinal (including the internal mammary, peridiaphragmatic, pericardial fat pad, or intercostal) lymph nodes. N2: Metastases in the contralateral mediastinal, ipsilateral, or contralateral supraclavicular lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIA Pleural Malignant Mesothelioma AJCC v8

Stage IIIA includes: T3, N1, M0. T3: Tumor is locally advanced but potentially resectable. The tumor involves all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of the endothoracic fascia, extension into the mediastinal fat, solitary, completely resectable focus of tumor extending into the soft tissues of the chest wall, and/or nontransmural involvement of the pericardium. N1: Metastases in the ipsilateral bronchopulmonary, hilar, or mediastinal (including the internal mammary, peridiaphragmatic, pericardial fat pad, or intercostal) lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage IV Pleural Malignant Mesothelioma AJCC v8

Stage IV includes: Any T, Any N, M1. M1: Distant metastasis present. (AJCC 8th ed.)


Stage IA Pleural Malignant Mesothelioma AJCC v8

Stage IA includes: T1, N0, M0. T1: Tumor limited to the ipsilateral parietal with or without involvement of visceral pleura, mediastinal pleura, and diaphragmatic pleura. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


Blasts 5 Percent or More of Bone Marrow Nucleated Cells

A microscopic finding indicating the presence of blasts constituting at least 5% of the nucleated cells in a bone marrow aspirate.


Unresectable Head and Neck Squamous Cell Carcinoma

A squamous cell carcinoma that arises from the head and neck region and is not amenable to surgical resection.


Stage 0 Lung Cancer AJCC v8

Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. Squamous cell carcinoma in situ (SCIS). Adenocarcinoma in situ (AIS): adenocarcinoma with pure lepidic pattern, 3 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage I Lung Cancer AJCC v8

Stage I includes: IA1: (T1mi, N0, M0); (T1a, N0, M0); IA2: (T1b, N0, M0); IA3: (T1c, N0, M0); IB: (T2a, N0, M0). T1mi: Minimally invasive adenocarcinoma: adenocarcinoma (3 cm or less in greatest dimension) with a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


Stage IA1 Lung Cancer AJCC v8

Stage IA1 includes: IA1: (T1mi, N0, M0); (T1a, N0, M0). T1mi: Minimally invasive adenocarcinoma: adenocarcinoma (3 cm or less in greatest dimension) with a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


Stage IA2 Lung Cancer AJCC v8

Stage IA2 includes: T1b, N0, M0. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


Stage IA3 Lung Cancer AJCC v8

Stage IA3 includes: T1c, N0, M0. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


Stage IB Lung Cancer AJCC v8

Stage IB includes: T2a, N0, M0. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


Stage II Lung Cancer AJCC v8

Stage II includes: IIA: (T2b, N0, M0); IIB: (T1a, N1, M0); (T1b, N1, M0); (T1c, N1, M0); (T2a, N1, M0); (T2b, N1, M0); (T3, N0, M0). T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension.  T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension.  T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIA Lung Cancer AJCC v8

Stage IIA includes: T2b, N0, M0. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension.  N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIB Lung Cancer AJCC v8

Stage IIB includes: (T1a, N1, M0); (T1b, N1, M0); (T1c, N1, M0); (T2a, N1, M0); (T2b, N1, M0); (T3, N0, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 8th ed.)


Stage III Lung Cancer AJCC v8

Stage III includes: IIIA: (T1a, N2, M0); (T1b, N2, M0); (T1c, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T4, N0, M0); (T4, N1, M0); IIIB: (T1a, N3, M0); (T1b, N3, M0); (T1c, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N2, M0); (T4, N2, M0); IIIC: (T3, N3, M0); (T4, N3, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIA Lung Cancer AJCC v8

Stage IIIA includes: (T1a, N2, M0); (T1b, N2, M0); (T1c, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T4, N0, M0); (T4, N1, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIB Lung Cancer AJCC v8

Stage IIIB includes: (T1a, N3, M0); (T1b, N3, M0); (T1c, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N2, M0); (T4, N2, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)


Stage IIIC Lung Cancer AJCC v8

Stage IIIC includes: (T3, N3, M0); (T4, N3, M0). T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)


Stage IV Lung Cancer AJCC v8

Stage IV includes: IVA: (Any T, Any N, M1a); (Any T, Any N, M1b); IVB: (Any T, Any N, M1c). M1a: Tumor with separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion. Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and not an exudate. If these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor. M1b: Tumor with single extrathoracic metastasis in a single organ (including involvement of a single nonregional node). M1c: Tumor with multiple extrathoracic metastases in a single organ or in multiple organs. (AJCC 8th ed.)


Stage IVA Lung Cancer AJCC v8

Stage IVA includes: (Any T, Any N, M1a); (Any T, Any N, M1b). M1a: Tumor with separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion. Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and not an exudate. If these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor. M1b: Tumor with single extrathoracic metastasis in a single organ (including involvement of a single nonregional node). (AJCC 8th ed.)


Stage IVB Lung Cancer AJCC v8

Stage IVB includes: Any T, Any N, M1c. M1c: Tumor with multiple extrathoracic metastases in a single organ or in multiple organs. (AJCC 8th ed.)


Refractory Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia that does not respond to treatment.


Recurrent Diffuse Intrinsic Pontine Glioma

The reemergence of diffuse intrinsic pontine glioma after a period of remission.


Refractory Diffuse Intrinsic Pontine Glioma

Diffuse intrinsic pontine glioma that is resistant to treatment.


IDH Family Wildtype

A genetic finding indicating that no nucleotide sequence change has been detected in any IDH family gene.


Blasts 10 Percent or More of Bone Marrow Nucleated Cells

A semi-quantitative microscopic finding indicating that at least 10 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.


Recurrent Cervical Adenocarcinoma

The reemergence of cervical adenocarcinoma after a period of remission.


Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8

Stage I includes: IA: (T1, N0, M0, G1, GX); IB: (T2, T3, T4, N0, M0, G1, GX). T1: Tumor measuring 5 cm or less in greatest dimension. T2: Tumor measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. T3: Tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. T4: Tumor measuring more than 15 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Total differentiation, mitotic count and necrosis score of 2 or 3. (AJCC 8th ed.)


Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8

Stage IA includes: T1, N0, M0, G1, GX. T1: Tumor measuring 5 cm or less in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Total differentiation, mitotic count and necrosis score of 2 or 3. (AJCC 8th ed.)


Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8

Stage IB includes: T2, T3, T4, N0, M0, G1, GX. T2: Tumor measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. T3: Tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. T4: Tumor measuring more than 15 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Total differentiation, mitotic count and necrosis score of 2 or 3. (AJCC 8th ed.)


Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8

Stage II includes: T1, N0, M0, G2, G3. T1: Tumor measuring 5 cm or less in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. G2: Total differentiation, mitotic count and necrosis score of 4 or 5. G3: Total differentiation, mitotic count and necrosis score of 6, 7, or 8. (AJCC 8th ed.)


Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8

Stage III includes: IIIA: (T2, N0, M0, G2, G3); IIIB: (T3, T4, N0, M0, G2, G3). T2: Tumor measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. T3: Tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. T4: Tumor measuring more than 15 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. G2: Total differentiation, mitotic count and necrosis score of 4 or 5. G3: Total differentiation, mitotic count and necrosis score of 6, 7, or 8. (AJCC 8th ed.)


Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8

Stage IIIA includes: T2, N0, M0, G2, G3. T2: Tumor measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. G2: Total differentiation, mitotic count and necrosis score of 4 or 5. G3: Total differentiation, mitotic count and necrosis score of 6, 7, or 8. (AJCC 8th ed.)


Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8

Stage IIIB includes: T3, T4, N0, M0, G2, G3. T3: Tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. T4: Tumor measuring more than 15 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. G2: Total differentiation, mitotic count and necrosis score of 4 or 5. G3: Total differentiation, mitotic count and necrosis score of 6, 7, or 8. (AJCC 8th ed.)


Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8

Stage IV includes: (Any T, N1, M0, Any G); (Any T, Any N, M1, Any G). N1: Regional lymph node metastasis. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)


Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8

Stage III includes: IIIA: (T3, N0, M0, High Mitotic Rate); IIIB: (T4, N0, M0, High Mitotic Rate). T3: Tumor measuring more than 5 cm but not more than 10 cm. T4: Tumor measuring more than 10 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. High Mitotic Rate: Over 5 mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)


Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8

Stage IV includes: (Any T, N1, M0, Any Mitotic Rate); (Any T, Any N, M1, Any Mitotic Rate). N1: Regional lymph node metastasis. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)


Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8

Stage III includes: IIIA: (T1, N0, M0, High Mitotic Rate); (T4, N0, M0, Low Mitotic Rate); IIIB: (T2, N0, M0, High Mitotic Rate); (T3, N0, M0, High Mitotic Rate); (T4, N0, M0, High Mitotic Rate). T1: Tumor measuring 2 cm or less. T2: Tumor measuring more than 2 cm but not more than 5 cm. T3: Tumor measuring more than 5 cm but not more than 10 cm. T4: Tumor measuring more than 10 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. High Mitotic Rate: Over 5 mitoses per 5 square millimeters, or per 50 HPF. Low Mitotic Rate: Five or fewer mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)


Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8


Stage IA Retroperitoneal Sarcoma AJCC v8


Stage IB Retroperitoneal Sarcoma AJCC v8


Stage II Retroperitoneal Sarcoma AJCC v8


Stage III Retroperitoneal Sarcoma AJCC v8

Stage III includes: IIIA: (T2, N0, M0, G2, G3); IIIB: (T3, T4, N0, M0, G2, G3); (Any T, N1, M0, Any G). T2: Tumor measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. T3: Tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. T4: Tumor measuring more than 15 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. N1: Regional lymph node metastasis. M0: No distant metastasis. G2: Total differentiation, mitotic count and necrosis score of 4 or 5. G3: Total differentiation, mitotic count and necrosis score of 6, 7, or 8. (AJCC 8th ed.)


Stage IIIA Retroperitoneal Sarcoma AJCC v8


Stage IIIB Retroperitoneal Sarcoma AJCC v8

Stage IIIB includes: (T3, T4, N0, M0, G2, G3); (Any T, N1, M0, Any G). T3: Tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. T4: Tumor measuring more than 15 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. N1: Regional lymph node metastasis. M0: No distant metastasis. G2: Total differentiation, mitotic count and necrosis score of 4 or 5. G3: Total differentiation, mitotic count and necrosis score of 6, 7, or 8. (AJCC 8th ed.)


Stage IV Retroperitoneal Sarcoma AJCC v8

Stage IV includes: Any T, Any N, M1, Any G. M1: Distant metastasis. (AJCC 8th ed.)


Clinical Stage III Merkel Cell Carcinoma AJCC v8

Stage III includes: T0-4, N1-3, M0. T0: No evidence of primary tumor. T1: Maximum clinical tumor diameter equal to or less than 2 cm. T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. T4: Primary tumor invades fascia, muscle, cartilage, or bone. N1: Metastasis in regional lymph node(s). N2: In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) without lymph node metastasis. N3: In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) with lymph node metastasis. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)


Clinical Stage IV Merkel Cell Carcinoma AJCC v8

Stage IV includes: T0-4, Any N, M1. T0: No evidence of primary tumor. T1: Maximum clinical tumor diameter equal to or less than 2 cm. T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. T4: Primary tumor invades fascia, muscle, cartilage, or bone. M1: Distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)


Pathologic Stage I Merkel Cell Carcinoma AJCC v8

Stage I includes: T1, N0, M0. T1: Maximum clinical tumor diameter equal to or less than 2 cm. N0: No regional lymph node metastasis detected on pathologic examination. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)


Pathologic Stage II Merkel Cell Carcinoma AJCC v8

Stage II includes: IIA: (T2-3, N0, M0); IIB: (T4, N0, M0). T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. T4: Primary tumor invades fascia, muscle, cartilage, or bone. N0: No regional lymph node metastasis detected on pathologic examination. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)


Pathologic Stage III Merkel Cell Carcinoma AJCC v8

Stage III includes: IIIA: (T1-4, N1a(sn) or N1a, M0); (T0, N1b, M0); IIIB: (T1-4, N1b-3, M0). T0: No evidence of primary tumor. T1: Maximum clinical tumor diameter equal to or less than 2 cm. T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. T4: Primary tumor invades fascia, muscle, cartilage, or bone. N1a(sn): Clinically occult regional lymph node metastasis identified only by sentinel lymph node biopsy. N1a: Clinically occult regional lymph node metastasis following lymph node dissection. N1b: Clinically and/or radiologically detected regional lymph node metastasis, microscopically confirmed. N2: In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) without lymph node metastasis. N3: In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) with lymph node metastasis. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)


Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8

Stage IIIA includes: (T1-4, N1a(sn) or N1a, M0); (T0, N1b, M0). T0: No evidence of primary tumor. T1: Maximum clinical tumor diameter equal to or less than 2 cm. T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. T4: Primary tumor invades fascia, muscle, cartilage, or bone. N1a(sn): Clinically occult regional lymph node metastasis identified only by sentinel lymph node biopsy. N1a: Clinically occult regional lymph node metastasis following lymph node dissection. N1b: Clinically and/or radiologically detected regional lymph node metastasis, microscopically confirmed. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)


Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8

Stage IIIB includes: T1-4, N1b-3, M0. T1: Maximum clinical tumor diameter equal to or less than 2 cm. T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. T4: Primary tumor invades fascia, muscle, cartilage, or bone. N1b: Clinically and/or radiologically detected regional lymph node metastasis, microscopically confirmed. N2: In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) without lymph node metastasis. N3: In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) with lymph node metastasis. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)


Pathologic Stage IV Merkel Cell Carcinoma AJCC v8

Stage IV includes: T0-4, Any N, M1. T0: No evidence of primary tumor. T1: Maximum clinical tumor diameter equal to or less than 2 cm. T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. T4: Primary tumor invades fascia, muscle, cartilage, or bone. M1: Distant metastasis microscopically confirmed. (AJCC 8th ed.)


Clinical Stage 0 Cutaneous Melanoma AJCC v8

Stage 0 includes: Tis, N0, M0. Tis: Melanoma in situ. Thickness: Not applicable. Ulceration status: Not applicable. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)


Clinical Stage I Cutaneous Melanoma AJCC v8

Stage I includes: IA: (T1a, N0, M0); IB: (T1b, N0, M0); (T2a, N0, M0). T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)


Clinical Stage IA Cutaneous Melanoma AJCC v8

Stage IA includes: T1a, N0, M0. T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)


Clinical Stage IB Cutaneous Melanoma AJCC v8

Stage IB includes: (T1b, N0, M0); (T2a, N0, M0). T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)


Clinical Stage II Cutaneous Melanoma AJCC v8

Stage II includes: IIA: (T2b, N0, M0); (T3a, N0, M0); IIB: (T3b, N0, M0); (T4a, N0, M0); IIC: (T4b, N0, M0). T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. T3b: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: With ulceration. T4a: Tumor measuring more than 4.0 mm in thickness. Ulceration status: Without ulceration. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration.  N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)


Clinical Stage IIA Cutaneous Melanoma AJCC v8

Stage IIA includes: (T2b, N0, M0); (T3a, N0, M0). T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)


Clinical Stage IIB Cutaneous Melanoma AJCC v8

Stage IIB includes: (T3b, N0, M0); (T4a, N0, M0). T3b: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: With ulceration. T4a: Tumor measuring more than 4.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)


Clinical Stage IIC Cutaneous Melanoma AJCC v8

Stage IIC includes: T4b, N0, M0. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration.  N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)


Clinical Stage III Cutaneous Melanoma AJCC v8

Stage III includes: Any T, Tis, N1 or More, M0. Tis: Melanoma in situ. Thickness: Not applicable. Ulceration status: Not applicable. N1: One tumor-involved node or in-transit, satellite, and/or microsatellite metastases with no tumor-involved nodes. N2: Two or three tumor-involved nodes or in-transit, satellite, and/or microsatellite metastases with one tumor-involved node. N3: Four or more tumor-involved nodes or in-transit, satellite, and/or microsatellite metastases with two or more tumor-involved nodes, or any number of matted nodes without or with in-transit, satellite, and/or microsatellite metastases. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)


Clinical Stage IV Cutaneous Melanoma AJCC v8

Stage IV includes: Any T, Any N, M1. M1: Evidence of distant metastasis. (AJCC 8th ed.)


Pathologic Stage 0 Cutaneous Melanoma AJCC v8


Pathologic Stage I Cutaneous Melanoma AJCC v8

Stage I includes: IA: (T1a, N0, M0); (T1b, N0, M0); IB: (T2a, N0, M0). T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)


Pathologic Stage IA Cutaneous Melanoma AJCC v8

Stage IA includes: (T1a, N0, M0); (T1b, N0, M0). T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)


Pathologic Stage IB Cutaneous Melanoma AJCC v8

Stage IB includes: T2a, N0, M0. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)


Pathologic Stage II Cutaneous Melanoma AJCC v8


Pathologic Stage IIA Cutaneous Melanoma AJCC v8


Pathologic Stage IIB Cutaneous Melanoma AJCC v8


Pathologic Stage IIC Cutaneous Melanoma AJCC v8


Pathologic Stage III Cutaneous Melanoma AJCC v8

Stage III includes: IIIA: (T1a/b-T2a, N1a or N2a, M0); IIIB: (T0, N1b, N1c, M0); (T1a/b-T2a, N1b/c or N2b, M0); (T2b/T3a, N1a-N2b, M0); IIIC: (T0, N2b, N2c, N3b or N3c); (T1a-T3a, N2c or N3a/b/c, M0); (T3b/T4a, Any N greater than or equal to N1, M0); (T4b, N1a-N2c, M0); IIID: (T4b, N3a/b/c, M0). T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. T0: No evidence of primary tumor (e.g., unknown primary or completely regressed melanoma). Thickness: Not applicable. Ulceration status: Not applicable. T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. T3b: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: With ulceration. T4a: Tumor measuring more than 4.0 mm in thickness. Ulceration status: Without ulceration. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration.  N1a: One clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No.  N2a: Two or three clinically occult nodal metastases (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N1b: One clinically detected nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: No. N1c: No regional lymph node disease. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N2b: Two or three nodal metastases at least one of which was clinically detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. N2c: One clinically occult nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N3b: Four or more nodal metastases, at least one of which was clinically detected, or presence of any number of matted nodes. Presence of in-transit, satellite, and/or microsatellite metastases: No. N3c: Two or more clinically occult nodal metastases. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N3a: Four or more clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)


Pathologic Stage IIIA Cutaneous Melanoma AJCC v8

Stage IIIA includes: T1a/b-T2a, N1a or N2a, M0. T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. N1a: One clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No.  N2a: Two or three clinically occult nodal metastases (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No.  M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)


Pathologic Stage IIIB Cutaneous Melanoma AJCC v8

Stage IIIB includes: (T0, N1b, N1c, M0); (T1a/b-T2a, N1b/c or N2b, M0); (T2b/T3a, N1a-N2b, M0). T0: No evidence of primary tumor (e.g., unknown primary or completely regressed melanoma). Thickness: Not applicable. Ulceration status: Not applicable. T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration.  T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. N1b: One clinically detected nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: No. N1c: No regional lymph node disease. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N2b: Two or three nodal metastases at least one of which was clinically detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. N1a: One clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N2a: Two or three clinically occult nodal metastases (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)


Pathologic Stage IIIC Cutaneous Melanoma AJCC v8

Stage IIIC includes: (T0, N2b, N2c, N3b or N3c); (T1a-T3a, N2c or N3a/b/c, M0); (T3b/T4a, Any N greater than or equal to N1, M0); (T4b, N1a-N2c, M0). T0: No evidence of primary tumor (e.g., unknown primary or completely regressed melanoma). Thickness: Not applicable. Ulceration status: Not applicable. T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. T3b: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: With ulceration. T4a: Tumor measuring more than 4.0 mm in thickness. Ulceration status: Without ulceration. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration.  N2b: Two or three nodal metastases at least one of which was clinically detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. N2c: One clinically occult nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N3b: Four or more nodal metastases, at least one of which was clinically detected, or presence of any number of matted nodes. Presence of in-transit, satellite, and/or microsatellite metastases: No. N3c: Two or more clinically occult nodal metastases. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N3a: Four or more clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N1a: One clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N1b: One clinically detected nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: No. N1c: No regional lymph node disease. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N2a: Two or three clinically occult nodal metastases (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)


Pathologic Stage IIID Cutaneous Melanoma AJCC v8

Stage IIID includes: T4b, N3a/b/c, M0. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration.  N3a: Four or more clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N3b: Four or more nodal metastases, at least one of which was clinically detected, or presence of any number of matted nodes. Presence of in-transit, satellite, and/or microsatellite metastases: No. N3c: Two or more clinically occult nodal metastases. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)


Pathologic Stage IV Cutaneous Melanoma AJCC v8

Stage IV includes: Any T, Tis, Any N, M1. Tis: Melanoma in situ. Thickness: Not applicable. Ulceration status: Not applicable. M1: Evidence of distant metastasis. (AJCC 8th ed.)


Blasts Under 5 Percent of Bone Marrow Nucleated Cells

A semi-quantitative microscopic finding indicating that less than 5 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.


PSA Level Greater than Ten

A blood concentration of prostate specific antigen greater than 10 ng/mL.


Human Immunodeficiency Virus Negative

Indicates that human immunodeficiency virus has not been detected in a sample.


Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells

A semi-quantitative microscopic finding indicating that at least 10 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells of myeloid origin.


PSA Level Greater than or Equal to Two

A blood concentration of prostate specific antigen greater than or equal to 2 ng/mL.


Mismatch Repair Protein Deficiency

A finding indicating that a cellular sample has a functional loss of a protein involved in the DNA mismatch repair process.


Refractory Pancreatic Neuroendocrine Carcinoma

Pancreatic neuroendocrine carcinoma that does not respond to treatment.


Recurrent Gray-Zone Lymphoma

The reemergence of gray-zone lymphoma after a period of remission.


Refractory Gray-Zone Lymphoma

Gray-zone lymphoma that is resistant to treatment.


Recurrent Central Nervous System Lymphoma

The reemergence of central nervous system lymphoma after a period of remission.


Refractory Central Nervous System Lymphoma

Central nervous system lymphoma that is resistant to treatment.


Recurrent Intravascular Large B-Cell Lymphoma

The reemergence of intravascular large B-cell lymphoma after a period of remission.


Refractory Intravascular Large B-Cell Lymphoma

Intravascular large B-cell lymphoma that is resistant to treatment.


Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

The reemergence of primary cutaneous diffuse large B-cell lymphoma, leg type after a period of remission.


Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Primary cutaneous diffuse large B-cell lymphoma, leg type that is resistant to treatment.


Blasts 10 Percent or More of Peripheral Blood White Cells

A semi-quantitative microscopic finding indicating that 10 percent or more of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.


Blasts Under 30 Percent of Bone Marrow Nucleated Cells

A semi-quantitative microscopic finding indicating that less than 30 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.


GPNMB Positive

An indication that GPNMB expression has been detected in a sample.


High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements

High-grade B-cell lymphoma characterized by the abnormal rearrangement of MYC gene, BCL2 gene, and/or BCL6 gene. Patients with this type of lymphoma usually respond poorly to standard treatments and have a poor prognosis.


HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

A large B-cell lymphoma characterized by the presence of a diffuse proliferation of large, atypical HHV8-positive neoplastic lymphocytes. It usually arises in association with HHV8-positive multicentric Castleman disease.


Liver Stiffness

The modulus of elasticity of the liver, representing the resistance of the liver to deformation. Liver stiffness has been shown to be a surrogate marker of advanced fibrosis and cirrhosis. Liver stiffness, measured by transient elastography, is an independent predictor of liver failure, hepatocellular carcinoma, and mortality in cirrhotic patients coinfected with the human immunodeficiency virus or acquired immune deficiency syndrome, and hepatitis C virus.


Double-Expressor Lymphoma

A diffuse large B-cell lymphoma characterized by double expression of MYC and BCL2 proteins without MYC and BCL2 gene aberrations. These lymphomas may have a worse prognosis than other diffuse large B-cell lymphomas, not otherwise specified, but they are not as aggressive as the high-grade B-cell lymphomas, with rearrangements of MYC and BCL2 and/or BCL6 genes.


Neoplastic Cells with Double Expression of MYC and BCL2 Proteins Present

An immunohistochemical finding indicating the presence of double expression of MYC and BCL2 proteins in the neoplastic cells of a tumor sample.


Body Mass Index Finding

The result of a body mass index measurement.


PDGFR Positive

Indicates that the expression of a member of the PDGFR family has been detected in a sample.


KIT Positive

Indicates that KIT expression has been detected in a sample.


PSA Level Greater than Two

A blood concentration of prostate specific antigen greater than 2 ng/mL.


High Risk Myelodysplastic Syndrome

Myelodysplastic syndrome with more than 4.5 to 6 points, according to the revised International Prognostic Scoring System (IPSS-R).


Recurrent High Risk Myelodysplastic Syndrome

The reemergence of high risk myelodysplastic syndrome after a period of remission.


Refractory High Risk Myelodysplastic Syndrome

High risk myelodysplastic syndrome that does not respond to treatment.


Refractory Soft Tissue Sarcoma

A soft tissue sarcoma that does not respond to treatment.


Florid Follicular Hyperplasia Post-Transplant Lymphoproliferative Disorder

An early lesion of post-transplant lymphoproliferative disorder with the morphologic appearance of florid follicular hyperplasia.


Advanced Head and Neck Squamous Cell Carcinoma

A head and neck squamous cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Anatomic Stage 0 Breast Cancer AJCC v8

Stage 0 includes: Tis, N0, M0. Tis: Ductal carcinoma in situ. Lobular carcinoma in situ is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Anatomic Stage I Breast Cancer AJCC v8

Stage I includes: IA: (T1, N0, M0); IB: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1mi: Tumor with micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Anatomic Stage IA Breast Cancer AJCC v8

Stage IA includes: T1, N0, M0. T1: Tumor measuring 20 mm or less in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Anatomic Stage IB Breast Cancer AJCC v8

Stage IB includes: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. N1mi: Tumor with micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Anatomic Stage II Breast Cancer AJCC v8

Stage II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0); IIB: (T2, N1, M0); (T3, N0, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Anatomic Stage IIA Breast Cancer AJCC v8

Stage IIA includes: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Anatomic Stage IIB Breast Cancer AJCC v8

Stage IIB includes: (T2, N1, M0); (T3, N0, M0). T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Anatomic Stage III Breast Cancer AJCC v8

Stage III includes: IIIA: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0); IIIB: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0); IIIC: (Any T, N3, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Anatomic Stage IIIA Breast Cancer AJCC v8

Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Anatomic Stage IIIB Breast Cancer AJCC v8

Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Anatomic Stage IIIC Breast Cancer AJCC v8

Stage IIIC includes: Any T, N3, M0. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Anatomic Stage IV Breast Cancer AJCC v8

Stage IV includes: Any T, Any N, M1. M1: Distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (AJCC 8th ed.)


Prognostic Stage 0 Breast Cancer AJCC v8

Stage 0 includes: Tis, N0, M0, G1-3, HER2 Status: Any, ER Status: Any, PR Status: Any. Tis: Ductal carcinoma in situ. Lobular carcinoma in situ is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)